by Mickael Marsali | Jun 20, 2016
MIT Technology Review had some interesting news to break today: the first proposed test of CRISPR gene-editing technology in human beings is being funded by none other than Internet billionaire Sean Parker, the well-known cofounder behind Napster and first president...
by Mickael Marsali | May 28, 2016
After a quarter century of conflict over genetically modified foods, it’s understandable that initial reactions to gene editing—the technical process of editing or removing specific genes of an organism—being applied to produce and livestock have been met with...
by Mickael Marsali | May 9, 2016
Novartis-backed, preclinical upstart Intellia Therapeutics ($NTLA) announced May 6th that it’s going for the top range of its IPO, selling 6 million shares at $18 a share to raise a total of $108 million. Founded in 2014, Intellia quickly caught the attention of...
by Mickael Marsali | Apr 12, 2016
Biotech companies pour millions of dollars into research programs every year, but the outcome is never guaranteed. The money used to fund this research can, in part, come from issuing stock or taking on debt. How much debt should be a concern for investors. Debt...
by Mickael Marsali | Mar 15, 2016
The biotech industry has some of the most interesting/bizarre trends you’ll find when researching investment opportunities. From prosthetic limbs to gene editing, biotechnology pushes the limits of what could be every day. One of the latest interesting trends to...
